Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Why don’t some patients take their medicines?

09.08.2005


Cost matters, but new VA / U-M study suggests lack of trust in doctors, depression play a big role too



Patients who trust their doctors are more likely to stick to their prescription medicines, even if they face high out-of-pocket costs, a new study finds. But patients who have lower levels of trust in their physicians, or who have depression-like symptoms, are much more likely to skip doses or refills when costs become a problem for them.
Those findings, from a new study of 912 patients with diabetes, provide evidence that the quality of the doctor-patient relationship can greatly affect patients’ medication use when drug costs become a burden. The study reinforces the importance of the doctor-patient relationship in helping patients adhere to medicines, and has implications for how doctors talk with patients -- not only about what a medicine will do for them, but also about their ability to pay for it and the availability of lower-cost options.

The research, from a team at the VA Ann Arbor Healthcare Center and the University of Michigan, will be published in the August 8/22 issue of the Archives of Internal Medicine. The data are from a larger VA-funded study of diabetes care at five health care systems around the nation.



Most of the patients in the study were men, half of them were over the age of 65, and the majority had household incomes under $25,000 a year. All patients were enrolled in the VA’s relatively generous prescription drug program, but a significant number reported cost-related problems in adhering to their medications.

The authors say the results provide insights into how cost, trust, mental health and income interact to influence patient behaviors toward prescription medications.

In all, nearly 30 percent of people who reported low levels of trust in their doctors and had monthly drug costs over $100 said they skipped medicines due to cost, compared with 11 percent of those who had a more trusting relationship with their doctor and the same level of cost. Among people with incomes under $10,000, cost affected adherence to drugs only among those with low physician trust.

Patients who reported experiencing symptoms of depression on a standardized scale were twice as likely to skip medicines due to cost as patients without depression. And patients who reported problems taking medications for other reasons were much more likely to report that they had cut back on medicine use due to cost.

"Our findings suggest that a trusting patient-physician relationship can significantly influence whether a person sticks to prescriptions when that patient faces pressures from their medication costs," says lead author John Piette, Ph.D.

Piette is a member of the VA Ann Arbor Center for Practice Management and Outcomes Research and associate professor in the general medicine division of the U-M Medical School.

Research has shown that skipping medications due to cost can seriously affect a person’s health. That’s especially true for people with chronic diseases, Piette says. The patients in the current study had diabetes, and 41 percent of them used insulin. People with diabetes who fail to take their medication as prescribed may have poor blood sugar control and a higher risk of heart attacks, strokes, blindness, kidney failure and amputation.

Piette notes that many patients who cut back on medication use due to cost do not tell their doctors. Last September, the VA/U-M team published findings in Archives of Internal Medicine showing that two-thirds of a nationwide sample of chronically ill patients who had cut back on their prescription drugs because of cost didn’t tell their doctors before they did it. And even after they had started skimping, 35 percent never told.

Despite the important role of medication costs in influencing patients’ adherence, Piette and colleagues note that most patients continue taking their medication as prescribed despite financial pressures, suggesting that there may be other influences at work for patients who respond to these costs with medication under-use.

"We need to understand better how chronically ill patients cope with their drug costs," he says. "We know that cost alone makes a big difference to people, but it’s not the only factor. The quality of patients’ relationships with their physician also appears to be key. The influence of depression is also important, as is a range of non-cost-related barriers to adherence."

Depression especially may lead people to feel fatalistic about their disease, overwhelmed by medication costs, and more likely to cut back on drug use as a result, Piette says.

In the VA study, depressive symptoms were common: nearly half of the low-trust group had depressive symptoms, compared with 35 percent of those reporting more physician trust. Even after controlling for other factors such as patients’ income and actual drug payments, depressed patients had twice the risk of cutting back on their pharmacotherapy due to cost. Identifying these patients and treating their depression may be an important component of an overall plan to support their medication use despite the burden of drug costs.

Piette says the message of this research for doctors is for them to recognize the multiple benefits from actively reaching out to establish trust with their patients, striving to form a strong therapeutic bond, and asking patients directly how drug costs are affecting them.

For patients, he says, "It’s important to be open and honest with your doctor regarding worries about how you’re going to pay for your medicines, as well as other things such as side effects and lifestyle issues that might keep you from taking your medications, and any depression-like symptoms such as prolonged sadness or sleep and appetite changes."

There may be opportunities for patients to lower their drug costs if they get their doctor involved, he explains, and patients may not appreciate the negative consequences of cutting back on drug use unless they discuss this with their doctors.

Kara Gavin | EurekAlert!
Further information:
http://www.umich.edu

More articles from Studies and Analyses:

nachricht The personality factor: How to foster the sharing of research data
06.09.2017 | ZBW – Leibniz-Informationszentrum Wirtschaft

nachricht Europe’s Demographic Future. Where the Regions Are Heading after a Decade of Crises
10.08.2017 | Berlin-Institut für Bevölkerung und Entwicklung

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: The fastest light-driven current source

Controlling electronic current is essential to modern electronics, as data and signals are transferred by streams of electrons which are controlled at high speed. Demands on transmission speeds are also increasing as technology develops. Scientists from the Chair of Laser Physics and the Chair of Applied Physics at Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) have succeeded in switching on a current with a desired direction in graphene using a single laser pulse within a femtosecond ¬¬ – a femtosecond corresponds to the millionth part of a billionth of a second. This is more than a thousand times faster compared to the most efficient transistors today.

Graphene is up to the job

Im Focus: LaserTAB: More efficient and precise contacts thanks to human-robot collaboration

At the productronica trade fair in Munich this November, the Fraunhofer Institute for Laser Technology ILT will be presenting Laser-Based Tape-Automated Bonding, LaserTAB for short. The experts from Aachen will be demonstrating how new battery cells and power electronics can be micro-welded more efficiently and precisely than ever before thanks to new optics and robot support.

Fraunhofer ILT from Aachen relies on a clever combination of robotics and a laser scanner with new optics as well as process monitoring, which it has developed...

Im Focus: The pyrenoid is a carbon-fixing liquid droplet

Plants and algae use the enzyme Rubisco to fix carbon dioxide, removing it from the atmosphere and converting it into biomass. Algae have figured out a way to increase the efficiency of carbon fixation. They gather most of their Rubisco into a ball-shaped microcompartment called the pyrenoid, which they flood with a high local concentration of carbon dioxide. A team of scientists at Princeton University, the Carnegie Institution for Science, Stanford University and the Max Plank Institute of Biochemistry have unravelled the mysteries of how the pyrenoid is assembled. These insights can help to engineer crops that remove more carbon dioxide from the atmosphere while producing more food.

A warming planet

Im Focus: Highly precise wiring in the Cerebral Cortex

Our brains house extremely complex neuronal circuits, whose detailed structures are still largely unknown. This is especially true for the so-called cerebral cortex of mammals, where among other things vision, thoughts or spatial orientation are being computed. Here the rules by which nerve cells are connected to each other are only partly understood. A team of scientists around Moritz Helmstaedter at the Frankfiurt Max Planck Institute for Brain Research and Helene Schmidt (Humboldt University in Berlin) have now discovered a surprisingly precise nerve cell connectivity pattern in the part of the cerebral cortex that is responsible for orienting the individual animal or human in space.

The researchers report online in Nature (Schmidt et al., 2017. Axonal synapse sorting in medial entorhinal cortex, DOI: 10.1038/nature24005) that synapses in...

Im Focus: Tiny lasers from a gallery of whispers

New technique promises tunable laser devices

Whispering gallery mode (WGM) resonators are used to make tiny micro-lasers, sensors, switches, routers and other devices. These tiny structures rely on a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

“Lasers in Composites Symposium” in Aachen – from Science to Application

19.09.2017 | Event News

I-ESA 2018 – Call for Papers

12.09.2017 | Event News

EMBO at Basel Life, a new conference on current and emerging life science research

06.09.2017 | Event News

 
Latest News

Nerves control the body’s bacterial community

26.09.2017 | Life Sciences

Four elements make 2-D optical platform

26.09.2017 | Physics and Astronomy

Goodbye, login. Hello, heart scan

26.09.2017 | Information Technology

VideoLinks
B2B-VideoLinks
More VideoLinks >>>